JP2008519840A - 糖尿病の処置方法 - Google Patents

糖尿病の処置方法 Download PDF

Info

Publication number
JP2008519840A
JP2008519840A JP2007541294A JP2007541294A JP2008519840A JP 2008519840 A JP2008519840 A JP 2008519840A JP 2007541294 A JP2007541294 A JP 2007541294A JP 2007541294 A JP2007541294 A JP 2007541294A JP 2008519840 A JP2008519840 A JP 2008519840A
Authority
JP
Japan
Prior art keywords
compound
optionally substituted
subject
formula
alkyl group
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
JP2007541294A
Other languages
English (en)
Japanese (ja)
Other versions
JP2008519840A5 (enExample
Inventor
セン・エイチ・チェン
ネルソン・エス・ユー
ロナルド・ケイ・シュール
チャオ・ホンメイ
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Genzyme Corp
Original Assignee
Genzyme Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genzyme Corp filed Critical Genzyme Corp
Publication of JP2008519840A publication Critical patent/JP2008519840A/ja
Publication of JP2008519840A5 publication Critical patent/JP2008519840A5/ja
Withdrawn legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/4025—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil not condensed and containing further heterocyclic rings, e.g. cromakalim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Diabetes (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Obesity (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
JP2007541294A 2004-11-10 2005-11-09 糖尿病の処置方法 Withdrawn JP2008519840A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US62644804P 2004-11-10 2004-11-10
PCT/US2005/040596 WO2006053043A2 (en) 2004-11-10 2005-11-09 Methods of treating diabetes mellitus

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2012225142A Division JP2013032377A (ja) 2004-11-10 2012-10-10 糖尿病の処置方法

Publications (2)

Publication Number Publication Date
JP2008519840A true JP2008519840A (ja) 2008-06-12
JP2008519840A5 JP2008519840A5 (enExample) 2009-01-08

Family

ID=35965895

Family Applications (4)

Application Number Title Priority Date Filing Date
JP2007541294A Withdrawn JP2008519840A (ja) 2004-11-10 2005-11-09 糖尿病の処置方法
JP2012225142A Pending JP2013032377A (ja) 2004-11-10 2012-10-10 糖尿病の処置方法
JP2014152732A Expired - Fee Related JP5837657B2 (ja) 2004-11-10 2014-07-28 糖尿病の処置方法
JP2015134366A Pending JP2015193638A (ja) 2004-11-10 2015-07-03 糖尿病の処置方法

Family Applications After (3)

Application Number Title Priority Date Filing Date
JP2012225142A Pending JP2013032377A (ja) 2004-11-10 2012-10-10 糖尿病の処置方法
JP2014152732A Expired - Fee Related JP5837657B2 (ja) 2004-11-10 2014-07-28 糖尿病の処置方法
JP2015134366A Pending JP2015193638A (ja) 2004-11-10 2015-07-03 糖尿病の処置方法

Country Status (6)

Country Link
US (3) US8003617B2 (enExample)
EP (1) EP1811991B1 (enExample)
JP (4) JP2008519840A (enExample)
BR (1) BRPI0517701A8 (enExample)
CA (1) CA2586761A1 (enExample)
WO (1) WO2006053043A2 (enExample)

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2011529500A (ja) * 2008-07-28 2011-12-08 ジェンザイム コーポレーション 虚脱性糸球体症および他の糸球体疾患の処置のためのグルコシルセラミドシンターゼ阻害
JP2012504608A (ja) * 2008-10-03 2012-02-23 ジェンザイム コーポレーション ２−アシルアミノプロパノール−タイプグルコシルセラミドシンターゼ抑制剤
JP2013512252A (ja) * 2009-11-27 2013-04-11 ジェンザイム・コーポレーション グルコシルセラミドシンターゼの阻害剤としての非晶質及び結晶型のｇｅｎｚ１１２６３８ヘミ酒石酸塩
JP2016535051A (ja) * 2013-10-29 2016-11-10 ビオマリン プハルマセウトイカル インコーポレイテッド グルコシルセラミドシンターゼ阻害剤としてのｎ−（１−ヒドロキシ−３−（ピロリジニル）プロパン−２−イル）ピロリジン−３−カルボキサミド誘導体

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006053043A2 (en) 2004-11-10 2006-05-18 Genzyme Corporation Methods of treating diabetes mellitus
PT2032134E (pt) * 2006-05-09 2015-10-07 Genzyme Corp Métodos de tratamento da doença do fígado gorduroso
WO2007149865A2 (en) * 2006-06-19 2007-12-27 University Of Utah Research Foundation Methods and compositions related to inhibition of ceramide synthesis
EP2594565B1 (en) 2007-05-31 2018-10-24 Genzyme Corporation 2-acylaminopropanol-type glucosylceramide synthase inhibitors
ES2660690T3 (es) * 2007-10-05 2018-03-23 Genzyme Corporation Método para tratar poliquistosis renales con derivados de ceramida
WO2010091104A1 (en) 2009-02-06 2010-08-12 Exelixis, Inc. Glucosylceramide synthase inhibitors
WO2010091164A1 (en) 2009-02-06 2010-08-12 Exelixis, Inc. Inhibitors of glucosylceramide synthase
CN107080747B (zh) 2011-03-18 2021-02-26 建新公司 葡萄糖基神经酰胺合酶抑制剂
WO2013078413A1 (en) * 2011-11-22 2013-05-30 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Modulators of lipid storage
JOP20130273B1 (ar) 2012-09-11 2021-08-17 Genzyme Corp مثبطات انزيم (سينثاز) غلوكوسيل سيراميد
WO2014150043A1 (en) 2013-03-15 2014-09-25 Concert Pharmaceuticals Inc. Inhibitors of the enzyme udp-glucose: n-acyl-sphingosine glucosyltransferase
AU2014235132B2 (en) 2013-03-15 2018-08-02 Genzyme Corporation Method of preparing glucosylceramide synthase inhibitors
JO3713B1 (ar) 2013-03-15 2021-01-31 Genzyme Corp أشكال ملح (s)-كوينوكليدين-3-يل(2-(2-(4-فلوروفينيل)ثيازول-4-يل)بروبان-2-يل)كارباميت
CN105745206B (zh) 2013-09-20 2019-08-13 生物马林药物股份有限公司 用于治疗疾病的葡萄糖神经酰胺合成酶抑制剂
WO2015059679A1 (en) * 2013-10-25 2015-04-30 Dr. Reddy's Laboratories Limited Improved process for the preparation of eliglustat
US9758044B2 (en) * 2014-10-02 2017-09-12 Ford Global Technologies, Llc Bus leakage resistance estimation for electrical isolation testing and diagnostics
KR101711706B1 (ko) * 2014-11-20 2017-03-02 주식회사 엘지화학 공통 모드 노이즈 시뮬레이터
CN107635980A (zh) 2015-03-11 2018-01-26 生物马林药物股份有限公司 用于治疗疾病的葡糖神经酰胺合酶抑制剂
WO2020026471A1 (ja) * 2018-07-31 2020-02-06 株式会社親広産業 グルコース消費促進剤および解糖系促進剤
PL4041733T3 (pl) 2019-11-15 2024-09-23 Yuhan Corporation Pochodne mające ugrupowanie 2,3-dihydro-1h-indenu lub 2,3-dihydrobenzofuranu lub ich farmaceutycznie dopuszczalne sole oraz kompozycje farmaceutyczne je zawierające
WO2021096241A1 (en) 2019-11-15 2021-05-20 Yuhan Corporation Novel compounds having inhibitory activity against glucosylceramide synthase or pharmaceutically acceptable salt thereof, processes for preparing the same, and pharmaceutical compositions comprising the same
JP2023512366A (ja) 2020-02-03 2023-03-27 ジェンザイム・コーポレーション リソソーム蓄積性疾患と関連する神経学的症状を処置するための方法
WO2022018695A1 (en) 2020-07-24 2022-01-27 Genzyme Corporation Pharmaceutical compositions comprising venglustat

Citations (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5302609A (en) * 1992-12-16 1994-04-12 The Regents Of The University Of Michigan Treatment of diabetic nephropathy
WO1997010817A1 (en) * 1995-09-20 1997-03-27 The Regents Of The University Of Michigan Amino ceramide-like compounds and therapeutic methods of use
WO2001054654A2 (en) * 2000-01-25 2001-08-02 The Gillette Company Reduction of hair growth
WO2003008399A1 (en) * 2001-07-16 2003-01-30 Genzyme Corporation Synthesis of udp-glucose: n-acylsphingosine glucosyltransferase inhibitors
US20030073680A1 (en) * 1995-09-20 2003-04-17 The Regents Of The University Of Michigan Amino ceramide-like compounds and therapeutic methods of use
JP2003521479A (ja) * 1999-07-09 2003-07-15 リージェンツ オブ ザ ユニバーシティ オブ ミシガン アミノセラミド様化合物および治療目的での使用方法
WO2003057874A1 (fr) * 2001-12-28 2003-07-17 Sumitomo Pharmaceuticals Company, Limited Marqueurs de maladies pour maladies renales et leur utilisation
JP2003238410A (ja) * 2002-02-21 2003-08-27 Seibutsu Yuki Kagaku Kenkyusho:Kk インスリン抵抗性解除剤
WO2006023827A2 (en) * 2004-08-20 2006-03-02 The Johns Hopkins University Methods for treatment of angiogenesis
WO2008150486A2 (en) * 2007-05-31 2008-12-11 Genzyme Corporation 2-acylaminopropoanol-type glucosylceramide synthase inhibitors

Family Cites Families (67)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1555654A (en) * 1977-06-25 1979-11-14 Exxon Research Engineering Co Agricultural burner apparatus
US4065562A (en) * 1975-12-29 1977-12-27 Nippon Shinyaku Co., Ltd. Method and composition for reducing blood glucose levels
NO154918C (no) * 1977-08-27 1987-01-14 Bayer Ag Analogifremgangsmaate til fremstilling av terapeutisk aktive derivater av 3,4,5-trihydroksypiperidin.
GB2020278B (en) * 1978-05-03 1983-02-23 Nippon Shinyaku Co Ltd Moranoline dervitives
JPS568318A (en) 1979-06-28 1981-01-28 Janssen Pharmaceutica Nv Non oral long acting composition of haloperidol and bromperidol derivative
GB8311286D0 (en) 1983-04-26 1983-06-02 Searle & Co Carboxyalkyl peptide derivatives
EP0144290A3 (de) 1983-12-01 1987-05-27 Ciba-Geigy Ag Substituierte Aethylendiaminderivate
US5041441A (en) * 1988-04-04 1991-08-20 The Regents Of The University Of Michigan Method of chemotherapy using 1-phenyl-2-decanoylamino-3-morpholino-1-propanol
JPH0416856A (ja) 1990-05-10 1992-01-21 Canon Inc 正帯電性非磁性トナー
US5399567A (en) * 1993-05-13 1995-03-21 Monsanto Company Method of treating cholera
WO1995005177A1 (en) * 1993-08-13 1995-02-23 Seikagaku Corporation Remedy for nervous diseases
PT742789E (pt) * 1994-02-02 2000-12-29 Liposome Co Inc Lipossomas e compostos farmaceuticamente activos e metodos para a sua utilizacao
DE69524592T2 (de) 1994-06-10 2002-07-18 Seikagaku Corp., Tokio/Tokyo 2-Acylaminopropanolverbindung und ihre pharmazeutische Zusammensetzung
US6255336B1 (en) * 1995-09-20 2001-07-03 The Regents Of The University Of Michigan Amino ceramide-like compounds and therapeutic methods of use
WO2001004108A1 (en) 1999-07-09 2001-01-18 Regents Of The University Of Michigan Amino ceramide-like compounds and therapeutic methods of use
NO965193L (no) * 1995-12-08 1997-06-09 Seikagaku Kogyo Kk Seikagaku C Aminalkoholderivat og fremgangsmåte for fremstilling derav
JP3993908B2 (ja) 1995-12-08 2007-10-17 生化学工業株式会社 アミノアルコール誘導体及び該誘導体の製造方法
JP4140984B2 (ja) 1995-12-20 2008-08-27 生化学工業株式会社 分化誘導作用を有する薬剤
US5972928A (en) * 1997-05-21 1999-10-26 Johns Hopkins University Methods for treatment of conditions associated with lactosylceramide
JP4036500B2 (ja) 1997-05-23 2008-01-23 生化学工業株式会社 アミノアルコール誘導体及びそれを含有する医薬
JP4176170B2 (ja) 1997-06-06 2008-11-05 生化学工業株式会社 アミノアルコール誘導体を含む医薬及び異常増殖性疾患治療薬
US6222619B1 (en) * 1997-09-18 2001-04-24 University Of Utah Research Foundation Diagnostic device and method
US6465488B1 (en) * 1997-12-11 2002-10-15 Chancellor, Masters & Scholars Of The University Of Oxford Inhibition of glycolipid biosynthesis
ES2285852T3 (es) * 1998-07-27 2007-11-16 Johns Hopkins University Compuestos de diamino-propanol para el tratamiento de la isquemia.
US6610703B1 (en) * 1998-12-10 2003-08-26 G.D. Searle & Co. Method for treatment of glycolipid storage diseases
GB0100889D0 (en) * 2001-01-12 2001-02-21 Oxford Glycosciences Uk Ltd Compounds
EP1384719A1 (en) 1999-07-09 2004-01-28 The Regents of The University of Michigan Inhibitors of the glucosyl ceramide synthase enzyme useful for the treatment of cancers, sphingolipidosis and microbial infections
US6407064B2 (en) 1999-12-06 2002-06-18 Seikagaku Corporation Aminoalcohol derivative and medicament comprising the same
JP5009459B2 (ja) 1999-12-06 2012-08-22 生化学工業株式会社 アミノアルコール誘導体及びそれを含有する医薬
CA2406067A1 (en) 2000-04-19 2001-11-01 Thomas Julius Borody Compositions comprising the combination of a bile acid and a fibrate for use in therapies for hyperlipidaemia-associated disorders
CA2432908A1 (en) 2000-12-20 2002-06-27 Bristol-Myers Squibb Pharma Company Diamines as modulators of chemokine receptor activity
WO2002053528A1 (en) 2000-12-29 2002-07-11 Wyeth Method for the regioselective preparation of substituted benzo[g]quinoline-3-carbonitriles and benzo[g]quinazolines
CA2434028C (en) 2001-01-10 2010-11-09 The Regents Of The University Of Michigan Amino ceramide-like compounds and therapeutic methods of use
US20020198240A1 (en) * 2001-01-10 2002-12-26 Shayman James A. Amino ceramide - like compounds and therapeutic methods of use
US7148251B2 (en) * 2001-01-10 2006-12-12 The Regents Of The University Of Michigan Amino ceramide-like compounds and therapeutic methods of use
US20040260099A1 (en) * 2001-01-10 2004-12-23 The Regents Of The University Of Michigan Amino ceramide-like compounds and therapeutic methods of use
US6835831B2 (en) * 2001-11-26 2004-12-28 Genzyme Corporation Diastereoselective synthesis of UDP-glucose: N-acylsphingosine glucosyltransferase inhibitors
GB0229931D0 (en) * 2002-12-21 2003-01-29 Astrazeneca Ab Therapeutic agents
HRP20040660B1 (hr) 2002-01-22 2012-10-31 Warner-Lambert Company Llc 2-(PIRIDIN-2-ILAMINO)-PIRIDO[2,3-d]PIRIMIDIN-7-ONI
EP1336411A1 (en) 2002-02-14 2003-08-20 Academisch Medisch Centrum bij de Universiteit van Amsterdam Compositions and methods for improving enzyme replacement therapy of lysosomal storage diseases
US6916802B2 (en) * 2002-04-29 2005-07-12 Genzyme Corporation Amino ceramide-like compounds and therapeutic methods of use
US20060217560A1 (en) * 2002-04-29 2006-09-28 Shayman James A Amino ceramide-like compounds and therapeutic methods of use
WO2004006756A2 (en) 2002-07-17 2004-01-22 Biogen Idec Ma Inc. THERAPIES FOR RENAL FAILURE USING INTERFERON-β
WO2004007453A1 (en) 2002-07-17 2004-01-22 Oxford Glycosciences (Uk) Ltd Piperidinetriol derivatives as inhibitors of glycosylceramide synthase
WO2004078194A1 (en) 2003-02-28 2004-09-16 Intermune, Inc. Interferon drug therapy for the treatment of viral diseases and liver fibrosis
GB0313678D0 (en) * 2003-06-13 2003-07-16 Oxford Glycosciences Uk Ltd Novel compounds
AU2004283631A1 (en) 2003-10-29 2005-05-06 Genzyme Corporation Use of a deoxynojirimycin derivative or a pharmaceutically salt thereof
EP1528056A1 (en) * 2003-10-29 2005-05-04 Academisch Ziekenhuis bij de Universiteit van Amsterdam Deoxynojirimycin analogues and their uses as glucosylceramidase inhibitors
JP2007516294A (ja) 2003-12-23 2007-06-21 エムユーエスシー ファウンデーション フォー リサーチ ディベロップメント 炎症性の疾患または症状の予防および治療のための方法および組成物
GB0400812D0 (en) 2004-01-14 2004-02-18 Celltech R&D Ltd Novel compounds
EP1576894A1 (en) * 2004-03-16 2005-09-21 Nederlandse Organisatie voor toegepast-natuurwetenschappelijk Onderzoek TNO The use of sphingolipids in the treatment and prevention of type 2 diabetes mellitus, insulin resistance and Metabolic Syndrome
DE602005026785D1 (de) * 2004-03-16 2011-04-21 Tno Verwendung von sphingolipiden bei der behandlung und vorbeugung von typ-2-diabetes mellitus, insulinresistenz und metabolismussyndrom
AU2005240714B2 (en) 2004-05-07 2011-07-07 Merck Patent Gmbh GM3 synthase as a therapeutic target in microvascular complications of diabetes
WO2005123055A2 (en) 2004-06-14 2005-12-29 Musc Foundation For Research Development Methods for treating inflammatory disorders
WO2006053043A2 (en) 2004-11-10 2006-05-18 Genzyme Corporation Methods of treating diabetes mellitus
HUE028654T2 (en) 2005-01-26 2016-12-28 Allergan Inc 3-aryl-3-hydroxy-2-aminopropionic amides, 3-heteroaryl-3-hydroxy-2-aminopropionic amides and related compounds having analgesic and / or immunostimulating activity
US8389472B2 (en) 2005-08-19 2013-03-05 Amylin Pharmaceuticals, Llc Exendin-4 to treat nonalcoholic steatohepatitis and nonalcoholic fatty liver disease
PT2032134E (pt) 2006-05-09 2015-10-07 Genzyme Corp Métodos de tratamento da doença do fígado gorduroso
WO2008011478A2 (en) 2006-07-19 2008-01-24 Allergan, Inc. Methods for treating chronic pain using 3-aryl-3-hydroxy-2-amino-propionic acid amides, 3-heteroaryl-3-hydroxy-2-amino-propionic acid amides and related compounds
WO2008011487A2 (en) 2006-07-19 2008-01-24 Allergan, Inc. L-benzyl-l-hydr0xy-2, 3-diamin0-propyl amines and 3-benzyl-3-hydroxy-2-amino-propionicacid amides for chronic pain
GB0614947D0 (en) 2006-07-27 2006-09-06 Isis Innovation Epitope reduction therapy
TWI389895B (zh) 2006-08-21 2013-03-21 Infinity Discovery Inc 抑制ｂｃｌ蛋白質與結合夥伴間之交互作用的化合物及方法
CA2677485A1 (en) 2007-02-09 2008-08-14 Irm Llc Compounds and compositions as channel activating protease inhibitors
ES2660690T3 (es) 2007-10-05 2018-03-23 Genzyme Corporation Método para tratar poliquistosis renales con derivados de ceramida
WO2009117150A2 (en) 2008-03-20 2009-09-24 Genzyme Corporation Method of treating lupus with ceramide derivatives
JP2011529500A (ja) 2008-07-28 2011-12-08 ジェンザイム コーポレーション 虚脱性糸球体症および他の糸球体疾患の処置のためのグルコシルセラミドシンターゼ阻害
CA2738768C (en) 2008-10-03 2017-10-31 Genzyme Corporation 2-acylaminopropoanol-type glucosylceramide synthase inhibitors

Patent Citations (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5302609A (en) * 1992-12-16 1994-04-12 The Regents Of The University Of Michigan Treatment of diabetic nephropathy
WO1997010817A1 (en) * 1995-09-20 1997-03-27 The Regents Of The University Of Michigan Amino ceramide-like compounds and therapeutic methods of use
US20030073680A1 (en) * 1995-09-20 2003-04-17 The Regents Of The University Of Michigan Amino ceramide-like compounds and therapeutic methods of use
JP2003521479A (ja) * 1999-07-09 2003-07-15 リージェンツ オブ ザ ユニバーシティ オブ ミシガン アミノセラミド様化合物および治療目的での使用方法
WO2001054654A2 (en) * 2000-01-25 2001-08-02 The Gillette Company Reduction of hair growth
WO2003008399A1 (en) * 2001-07-16 2003-01-30 Genzyme Corporation Synthesis of udp-glucose: n-acylsphingosine glucosyltransferase inhibitors
WO2003057874A1 (fr) * 2001-12-28 2003-07-17 Sumitomo Pharmaceuticals Company, Limited Marqueurs de maladies pour maladies renales et leur utilisation
JP2003238410A (ja) * 2002-02-21 2003-08-27 Seibutsu Yuki Kagaku Kenkyusho:Kk インスリン抵抗性解除剤
WO2006023827A2 (en) * 2004-08-20 2006-03-02 The Johns Hopkins University Methods for treatment of angiogenesis
WO2008150486A2 (en) * 2007-05-31 2008-12-11 Genzyme Corporation 2-acylaminopropoanol-type glucosylceramide synthase inhibitors

Non-Patent Citations (7)

* Cited by examiner, † Cited by third party
Title
AKIRA ABE ET AL., ANLYTICAL BIOCHEMISTRY, vol. 287, JPN6012030039, 2000, pages 344 - 347, ISSN: 0002248870 *
AKIRA ABE ET AL., JOURNAL OF LIPID RESEARCH, vol. 36, JPN6012030041, 1995, pages 611 - 621, ISSN: 0002248872 *
LIHSUEH LEE ET AL., THE JOURNAL OF BIOLOGICAL CHEMISTRY, vol. Vol.274(21), JPN6012030040, 1999, pages 14662 - 14669, ISSN: 0002248871 *
MASAYUKI JIMBO ET AL., J. BIOCHEM., vol. 127, JPN6012030036, 2000, pages 485 - 491, ISSN: 0002248867 *
NAOKI ASANO, GLYCOBIOLOGY, vol. Vol.13(10), JPN6012030037, 2003, pages 93 - 104, ISSN: 0002248868 *
SEIICHI TAGAMI ET AL., THE JOURNAL OF BIOLOGICAL CHEMISTRY, vol. Vol.277(5), JPN6012005623, 2002, pages 3085 - 3092, ISSN: 0002140216 *
STEVEN B. LEVERY ET AL., FEBS LETTERS, vol. 525, JPN6012030038, 2002, pages 59 - 64, ISSN: 0002248869 *

Cited By (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2015131839A (ja) * 2008-07-28 2015-07-23 ジェンザイム コーポレーション 虚脱性糸球体症および他の糸球体疾患の処置のためのグルコシルセラミドシンターゼ阻害
JP2011529500A (ja) * 2008-07-28 2011-12-08 ジェンザイム コーポレーション 虚脱性糸球体症および他の糸球体疾患の処置のためのグルコシルセラミドシンターゼ阻害
JP2012504608A (ja) * 2008-10-03 2012-02-23 ジェンザイム コーポレーション ２−アシルアミノプロパノール−タイプグルコシルセラミドシンターゼ抑制剤
JP2016138124A (ja) * 2009-11-27 2016-08-04 ジェンザイム・コーポレーション グルコシルセラミドシンターゼの阻害剤としての非晶質及び結晶型のｇｅｎｚ１１２６３８ヘミ酒石酸塩
KR20150125734A (ko) * 2009-11-27 2015-11-09 젠자임 코포레이션 글루코실세라마이드 신타아제의 억제제로서 ｇｅｎｚ 112638 헤미타르타르산염의 무정형 및 결정질 형태
JP2015212291A (ja) * 2009-11-27 2015-11-26 ジェンザイム・コーポレーションＧｅｎｚｙｍｅ Ｃｏｒｐｏｒａｔｉｏｎ グルコシルセラミドシンターゼの阻害剤としての非晶質及び結晶型のｇｅｎｚ１１２６３８ヘミ酒石酸塩
JP2013512252A (ja) * 2009-11-27 2013-04-11 ジェンザイム・コーポレーション グルコシルセラミドシンターゼの阻害剤としての非晶質及び結晶型のｇｅｎｚ１１２６３８ヘミ酒石酸塩
JP2019001809A (ja) * 2009-11-27 2019-01-10 ジェンザイム・コーポレーション グルコシルセラミドシンターゼの阻害剤としての非晶質及び結晶型のｇｅｎｚ１１２６３８ヘミ酒石酸塩
KR102073207B1 (ko) 2009-11-27 2020-02-05 젠자임 코포레이션 글루코실세라마이드 신타아제의 억제제로서 ｇｅｎｚ 112638 헤미타르타르산염의 무정형 및 결정질 형태
JP2020189873A (ja) * 2009-11-27 2020-11-26 ジェンザイム・コーポレーション グルコシルセラミドシンターゼの阻害剤としての非晶質及び結晶型のｇｅｎｚ１１２６３８ヘミ酒石酸塩
JP7150528B2 (ja) 2009-11-27 2022-10-11 ジェンザイム・コーポレーション グルコシルセラミドシンターゼの阻害剤としての非晶質及び結晶型のｇｅｎｚ１１２６３８ヘミ酒石酸塩
JP2023116764A (ja) * 2009-11-27 2023-08-22 ジェンザイム・コーポレーション グルコシルセラミドシンターゼの阻害剤としての非晶質及び結晶型のｇｅｎｚ１１２６３８ヘミ酒石酸塩
JP2016535051A (ja) * 2013-10-29 2016-11-10 ビオマリン プハルマセウトイカル インコーポレイテッド グルコシルセラミドシンターゼ阻害剤としてのｎ−（１−ヒドロキシ−３−（ピロリジニル）プロパン−２−イル）ピロリジン−３−カルボキサミド誘導体

Also Published As

Publication number Publication date
CA2586761A1 (en) 2006-05-18
EP1811991A2 (en) 2007-08-01
JP2014240402A (ja) 2014-12-25
US9532976B2 (en) 2017-01-03
JP2013032377A (ja) 2013-02-14
BRPI0517701A8 (pt) 2018-01-23
JP2015193638A (ja) 2015-11-05
WO2006053043A3 (en) 2006-08-24
JP5837657B2 (ja) 2015-12-24
BRPI0517701A (pt) 2008-10-21
US20080161379A1 (en) 2008-07-03
EP1811991B1 (en) 2018-11-07
US8003617B2 (en) 2011-08-23
US20150190373A1 (en) 2015-07-09
WO2006053043A2 (en) 2006-05-18
US20120022126A1 (en) 2012-01-26

Similar Documents

Publication Publication Date Title
JP5837657B2 (ja) 糖尿病の処置方法
US8961959B2 (en) Glucosylceramide synthase inhibitors and therapeutic methods using the same
RU2581058C2 (ru) Новые композиции для предупреждения и/или лечения дегенеративных расстройств центральной нервной системы
WO2021231646A1 (en) Combination treatment of liver disorders
US20130123248A1 (en) Pharmacological modulation of positive ampa receptor modulator effects on neurotrophin expression
US11938122B2 (en) 5-[[4-[2-[5-(1-hydroxyethyl)pyridin-2-yl]ethoxy]phenyl]methyl]-1,3- thiazolidine-2,4-dione for treating nonalcoholic fatty liver disease
JP2005519927A (ja) 多嚢胞性卵巣症候群の処置における、シルデナフィル如きｐｄｅ５インヒビターの使用
ES2327639T3 (es) Uso de derivados de ftalida para el tratamiento y prevecion de diabetes mellitus.
KR20020073176A (ko) 불안증 개선 방법
JP2010518860A (ja) Ｌｙｎキナーゼの活性化剤の同定方法
CN114929218A (zh) 使用整联蛋白抑制剂组合治疗肝脏疾病
AU2024219449A1 (en) Compositions and methods of use of gamma-ketoaldehyde scavengers for treating, preventing or improving fibrosis of the liver
JP2008530198A (ja) ４−ヒドロキシイソロイシンのジアステレオ異性体及びこれらの使用
TW201818964A (zh) 使用色胺酸羥化酶抑制劑之方法
JP5564263B2 (ja) ムスカリンｍ１、ｍ２およびｍ３受容体の選択的阻害を有する薬剤の製造のための１０−［（３ｒ）−１−アザビシクロ［２．２．２］オクト−３−イルメチル］−１０ｈ−フェノチアジンの使用
US20250302823A1 (en) Compositions and methods for treating hepatic porphyrias with glycine transport inhibitors
US20230355625A1 (en) Methods of treatment
US20070105878A1 (en) Purine formulations and methods for managing disorders
CN121335698A (zh) 用于治疗肝脏病症或心脏代谢疾病的包含THR-β激动剂和GLP-1R激动剂的组合
HK40014768B (en) 5-[[4-[2-[5-(1-hydroxyethyl)pyridin-2-yl]ethoxy]ph-enyl]methyl]-1,3-thiazolidine-2,4-dione for treating nonalcoholic fatty liver disease
HK40014768A (en) 5-[[4-[2-[5-(1-hydroxyethyl)pyridin-2-yl]ethoxy]ph-enyl]methyl]-1,3-thiazolidine-2,4-dione for treating nonalcoholic fatty liver disease
WO2007004226A2 (en) Compositions and methods for treatment of male erectile dysfunction (ed)

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20081107

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20081107

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20120207

RD04 Notification of resignation of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7424

Effective date: 20120309

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20120507

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20120612

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20120912

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20120920

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20121010

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20121225

A761 Written withdrawal of application

Free format text: JAPANESE INTERMEDIATE CODE: A761

Effective date: 20130425